Can a blood test and MRI tailor cancer therapy to each patient?

NCT ID NCT07762976

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests whether giving extra chemotherapy or a combination of chemotherapy and immunotherapy after standard treatment can improve outcomes for people with nasopharyngeal carcinoma. The choice of treatment is based on each patient's risk level, determined by changes in a blood marker (EBV-DNA) and MRI scans. The goal is to see if this personalized approach can reduce the chance of the cancer coming back or spreading.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adjuvant therapy with capecitabine alone or combined with tislelizumab, guided by risk assessment
What this could lead to: If successful, this approach could personalize adjuvant treatment for nasopharyngeal carcinoma, potentially improving survival and reducing unnecessary side effects.
What could go wrong: This is a phase II trial, so results are preliminary. The benefit may be modest, and adding immunotherapy could increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA (NPC)

Contacts and locations

Locations

Fudan Universtiy Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.